A focused course, tailored for you
Bulge-Bracket Risk Management Director's Strategic-Authority Playbook
How a Risk Management Director (AVP) at a bulge-bracket bank reframes the seat as strategic risk authority when cost-per-revenue cycles reach risk functions.
When cost-per-revenue cycles reach the risk management function, Directors without published authority narratives read as cost-of-coverage.
$199 one-time
Tailored to your situation. Access within 24 hours. 30-day money-back.
Includes a hand-built implementation playbook delivered alongside course access, generated for your specific situation.
Why this course
Bulge-bracket banks running cost-per-revenue cycles reach risk management functions in the same review as the front office. MDs above are protected by board-level authority; VPs below are protected by their direct contribution. The Director layer is the band the deck reviews most carefully.
The Risk Management Directors who survive own a defensible risk-authority narrative with measurable risk and business outcomes, an executive-relationship map across business-line leaders and regulators, and a quarterly risk-state artefact the CRO and risk committee adopt.
The course covers the three artefacts and the 90-day path to strategic-authority framing. Plus a hand-built implementation playbook against your real risk scope.
The 12 modules
Module 1. Reading the cost-per-revenue review for risk implications
Cost-per-revenue cycles at bulge-bracket banks reach risk functions in three phases: enterprise cost review, second-line review, and Director-portfolio review. The diagnostic decodes which signals (front-office margin compression, regulatory-capital efficiency targets, risk-function FTE-to-revenue ratios, stress-test outcomes) indicate that risk management is in the redraw set. Which Directors survive on regulatory cover alone and which survive on documented business-line and regulator authority.
Module 2. Generic Risk Director vs strategic risk authority
Two structurally different framings of the same Risk Management Director seat read very differently to the cost-per-revenue review. Generic Director shows up as coverage-of-regulatory-cost. Strategic risk authority shows up as the leadership the business lines and regulators rely on: documented loss-prevention outcomes, regulator-relationship depth, and business-line sponsor protection through stress cycles. The three artefacts that mark the shift.
Module 3. Your defensible risk-authority narrative
Construct the risk-authority narrative as a CRO-grade two-page document anchored to measurable risk and business outcomes: loss prevented (with worked-example cases), exposure managed across cycles, regulatory matters resolved without finding, and capital efficiency gained. Three structural templates (market-risk-anchored, credit-risk-anchored, operational-risk-anchored) and the formula for choosing the template that fits your portfolio. Worked examples from bulge-bracket Risk Directors.
Module 4. Executive-relationship map
Map your relationships across business-line sponsors (trading desk heads, banking division leads, prime-services and wealth heads), second-line peers (audit, compliance, legal), and regulators (Fed, OCC, FINRA, PRA depending on jurisdiction). Format: relationship name, sponsorship-level, last meaningful regulatory or business interaction, and current dependency status. The map the CRO cites by Director name in cost-per-revenue reviews.
Module 5. Quarterly risk-state artefact for CRO and risk committee
The quarterly artefact is a two-page state document covering risk portfolio momentum, business-line dependency status, regulatory positioning, stress-test outcomes, capital efficiency, and emerging risks. Cadence is end-of-quarter delivery to CRO with risk-committee distribution. Format aligns with risk-committee read style (executive summary, three risk vectors, action register). Three worked examples from real bulge-bracket Risk Director portfolios at different cost-per-revenue stages.
Module 6. Working with audit, compliance, and second line
Risk overlaps audit (independent review), compliance (regulatory adherence), and legal (regulatory-matter resolution). The collaboration pattern that strengthens defensibility positioning: shared regulator interactions, joint second-line reviews, cross-function risk-and-compliance teams credited by Director name. Examples of joint second-line narratives that elevated a Risk Director to MD and how to document the partnership for the CRO.
Module 7. Regulatory considerations: Basel, CCAR, FRTB, stress testing
Risk management is heavily regulated under Basel III/IV (capital adequacy), CCAR (comprehensive capital analysis), FRTB (fundamental review of trading book), DFAST stress tests, and SR letters from the Fed. The compliance overlays that strengthen the Director narrative as regulator-grade risk leadership. How to position regulatory rigor as Director-grade IP that the CRO cites in capital efficiency narratives to the board.
Module 8. Cross-business leverage
Reusable Director practices that scale across business lines: risk-framework templates, second-line review cadences, regulator-interaction protocols, scenario-design templates for stress testing. The leverage pattern that signals Director-grade leadership rather than vertical coverage. How to convert delivered risk work into published methodology the CRO cites in board-level capital-efficiency narratives.
Module 9. Client-confidence narrative through cycle
Risk decisions affect client confidence in counterparty strength, especially through stress cycles (margin calls, prime-services exposure, banking division capital allocation). The client-confidence narrative documents how risk leadership preserved business-line client relationships through stress events. Three patterns (counterparty-credit anchor, market-risk transparency anchor, operational-resilience anchor) and how to document each for the risk-authority narrative.
Module 10. Scope statement: Director vs MD / Head of Risk
Two overlapping seats with different scopes. Director scope covers risk-portfolio delivery, second-line partnership, IP authorship at portfolio level. MD scope adds risk-function ownership across business lines, succession sponsorship, cross-portfolio leverage, board-committee participation. Head of Risk scope adds enterprise risk P&L and risk-committee chair responsibilities. The scope statement that puts you in the MD track defensibly.
Module 11. Promotion mechanics inside bulge-bracket risk
Internal path from Director to MD to Head of Risk. The promotion artefact (risk-authority narrative, regulator-relationship record, business-line partnership outcomes, capital-efficiency contribution) and the cycle calendar (Q1 nomination, Q2 review, Q3 partnership vote, Q4 announcement). What gets a Risk Director shortlisted, what blocks a Director who is otherwise qualified, and how to time your move with the CRO's succession plan.
Module 12. Your 90-day move to strategic-authority framing
Day-by-day plan with daily artefacts. Days 1-7: risk-authority narrative scaffold drafted from your loss-prevention and regulator-interaction history. Days 8-21: relationship map v1 completed with business-line sponsor and regulator dependencies confirmed. Days 22-45: quarterly artefact v1 delivered to CRO and risk committee. Days 46-60: risk-function ownership conversation. Days 61-90: MD conversation scheduled with sponsor identified in module 11.
How this addresses your situation
Specific modules that map to what you said you are dealing with.
Modules 1 and 2 cover the diagnostic.
Modules 3 to 5 produce the three artefacts.
Modules 6 to 9 cover cross-function cadence, regulatory, leverage, and client confidence.
Modules 10 to 12 cover scope, promotion, and 90-day execution.
